Hims stock reversed lower Wednesday as analysts laid out low expectations for Him & Hers' branded tirzepatide.

The telehealth company is offering Lilly’s branded form of tirzepatide—approved for weight loss—on its site for $1,899 a ...

The woman wants to name her baby after her paternal grandmother, two years after her sister named her child after their ...

Eli Lilly is on Trump’s list as having committed $27 billion in investments. But that’s on top of an earlier commitment. In ...

Heart disease experts are hailing the results of a clinical trial showed a strongly positive performance by a drug that ...

Pfizer in 2019 sold $20 billion of drugs in the U.S. Its federal tax bill? Zero. That revelation was part of a Senate Finance ...

Directors of five NIH institutes have been placed on administrative leave or offered new assignments as part of sweeping HHS ...

Zepbound is made by drugmaker Eli Lilly. While Hims & Hers offers it for $1,899 per month, Lilly said the price on its own LillyDirect platform starts at $349 for self-paying customers. With insurance ...

Telehealth firm Hims & Hers Health on Tuesday announced that it plans to sell Eli Lilly’s weight-loss drug. This comes after ...

Viking Therapeutics (NASDAQ: VKTX) is operating in one of the highest-growth pharma areas around. Viking doesn't sell weight ...

Pharmaceutical companies are urging US President Donald Trump to implement tariffs on imported drugs gradually, aiming to ...

Even statins don’t work on risk factor called lipoprotein (a) that quickly clings to arteries and narrows them ...